Efficacy and Safety of Gosogliptin as Monotherapy and in Combination With Metformin vs. Vildagliptin as Monotherapy and in Combination With Metformin in Drug-naive Type 2 Diabetic Patients.
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 299 participants.
Also called NCT03088670
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 299 participants
- Sponsor
- SatRx LLC
- Registry
-
NCT03088670
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Russia
- Registry status
- Completed
Technical summary
Registry record NCT03088670. Randomized; no masking; primary purpose treatment. Start 2013-04-23 (actual); primary completion 2014-03-30 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Gosogliptin as Monotherapy and in Combination With Metformin vs. Vildagliptin as Monotherapy and in Combination With Metformin in Drug-naive Type 2 Diabetic Patients.
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Gosogliptin
- Intervention (Drug)
- Vildagliptin
- Intervention (Drug)
- Metformin
- Lead sponsor
- SatRx LLC
Record details
- Record id
cardio:ct-nct03088670- Content hash
f77671f83cc202863e5d9c8fffa5e8ae7f659505d8928cc1417dd599a1cbd623